Sociedad Americana de Hirudoterapia

Characterization of a Fatty Acid Amide Hydrolase (FAAH) in Hirudo Verbana

Basic science published in Neurochem Res (2024)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Genómica y proteómicaFarmacología salivalKabeiseman E et al. · Neurochemical research, 2024

Abstract

The endocannabinoid system plays a critical role in modulating both peripheral and central nervous system function. Despite being present throughout the animal kingdom, there has been relatively little investigation of the endocannabinoid system beyond traditional animal models. In this study, we report on the identification and characterization of a putative fatty acid amide hydrolase (FAAH) in the medicinal leech, Hirudo verbana. FAAH is the primary enzyme responsible for metabolizing the endocannabinoid signaling molecule arachidonoyl ethanolamide (anandamide or AEA) and therefore plays a critical role in regulating AEA levels in the nervous system. mRNA encoding Hirudo FAAH (HirFAAH) is expressed in the leech central nervous system (CNS) and sequence analysis suggests that this is an orthologue of FAAH-2 observed in vertebrates. Functionally, HirFAAH has serine hydrolase activity based on activity-based protein profiling (ABPP) studies using the fluorophosphonate probe TAMRA-FP. HirFAAH also hydrolyzes arachidonyl 7-amino, 4-methyl coumarin amide (AAMCA), a substrate specific to FAAH. Hydrolase activity during both the ABPP and AAMCA assays was eliminated by a mutation at a conserved catalytic serine. Activity was also blocked by the known FAAH inhibitor, URB597. Treatment of Hirudo ganglia with URB597 potentiated synapses made by the pressure-sensitive mechanosensory neuron (P cell), mimicking the effects of exogenously applied AEA. The Hirudo CNS has been a useful system in which to study properties of endocannabinoid modulation of nociception relevant to vertebrates. Therefore, this characterization of HirFAAH is an important contribution to comparative studies of the endocannabinoid system.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAmidohydrolasesAnimalsLeechesEndocannabinoidsAmino Acid SequenceFatty Acid Amide HydrolasesAnimals, Poisonous

Resumen

Identifies and characterizes a FAAH-2 orthologue (HirFAAH) in Hirudo verbana central nervous system that hydrolyzes anandamide and is blocked by URB597, establishing endocannabinoid metabolism in medicinal leeches.

Por qué esto importa para la hirudoterapia

This study reports the identification and characterization of a putative fatty acid amide hydrolase (FAAH) in the medicinal leech Hirudo verbana, the primary enzyme responsible for metabolizing the endocannabinoid anandamide (AEA). The authors demonstrate that HirFAAH is expressed in the leech CNS, exhibits serine hydrolase activity confirmed by activity-based protein profiling and substrate assays, and that pharmacological inhibition with URB597 potentiated synaptic signaling in pressure-sensitive mechanosensory neurons, mimicking exogenous AEA effects. The study does not mention hirudotherapy, therapeutic applications of leeches, or their secretome. Relevance to ASH's domain is indirect; this is purely basic comparative neuroscience investigating endocannabinoid signaling in Hirudo verbana.

Citación

Characterization of a Fatty Acid Amide Hydrolase (FAAH) in Hirudo Verbana.

Kabeiseman E et al. · Neurochemical research, 2024

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.